Nuvectis Pharma (NVCT) Accounts Payables (2021 - 2026)

Nuvectis Pharma has disclosed Accounts Payables across 6 years of filings, most recently posting $4.7 million for Q1 2026.

• Accounts Payables for Q1 2026 came in at $4.7 million, up 56.92% year-over-year; the trailing twelve-month figure through Mar 2026 was $4.7 million (up 56.92% YoY), and the FY2025 annual result was $6.3 million, up 151.16% from the prior year.
• Accounts Payables came in at $4.7 million for Q1 2026 at Nuvectis Pharma, down from $6.3 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $6.4 million in Q3 2025 to a low of $1.3 million in Q1 2022.
• The 5-year median for Accounts Payables is $2.5 million (2024), against an average of $3.0 million.
• Across the five-year window, Accounts Payables tumbled 35.25% in 2024 and soared 184.79% in 2025, its largest moves.
• Nuvectis Pharma's Accounts Payables stood at $2.9 million in 2022, then retreated by 4.78% to $2.8 million in 2023, then slipped by 9.85% to $2.5 million in 2024, then surged by 151.16% to $6.3 million in 2025, then fell by 25.17% to $4.7 million in 2026.
• The last three Accounts Payables figures came in at $4.7 million (Q1 2026), $6.3 million (Q4 2025), and $6.4 million (Q3 2025), per Business Quant data.